In NSCLC patients treated with the EGFR inhibitor gefitinib, patients with specific in-frame indel mutations in the EGFR gene were more sensitive to gefitinib, as these mutations increase the tumor’s dependence on growth factor signaling, compared to patients without such mutations. This evidence concerns the gene EGFR and neoplasm.